著者

小澤 秀介 小林 愛子 高津 亜希子 神田 博仁 山折 大 塩沢 丹里 大森 栄

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.42, no.3, pp.202-208, 2016-03-10 (Released:2017-03-16)

参考文献数

20

---

We report the case of a 35-year-old pregnant woman treated with the calcium channel blocker, nifedipine, for maintenance tocolysis. She was hospitalized due to preterm labor at 21 weeks of gestation by her previous physician. A rash appeared following ritodrine hydrochloride administration for maintenance tocolysis. After changing to magnesium sulfate, a rash appeared again. As these rashes were suspected to have been induced by ritodrine hydrochloride and magnesium sulfate independently, consecutive treatment with these drugs was difficult. Therefore, she was transferred to our hospital for follow-up. At 28 weeks 6 days of gestation, treatment with nifedipine for maintenance tocolysis was started after receiving written informed consent, and the medication was approved by the institutional review board of our hospital. The attending pharmacist considered fetal/neonatal adverse effects of nifedipine, such as teratogenicity, fetotoxicity, and neonatal complications, as well as maternal side effects, such as headache, constipation, and excessive blood pressure drop. The pharmacist provided drug information about nifedipine to the attending physicians and nurses, and gave medication counseling to the patient. Following oral administration of 80 mg of nifedipine daily (20 mg every 6 hours), headache and constipation were evident but gradually improved. Neither excessive blood pressure drop nor exacerbated uterine contraction was observed throughout the period of nifedipine treatment. This medication was finished at 34 weeks 5 days of gestation and the patient was discharged at 36 weeks 2 days of gestation. She delivered a baby at 40 weeks 3 days of gestation.

著者

松永 民秀 丸山 昌孝 大森 栄

出版者

The Shinshu Medical Society

雑誌

信州医学雑誌 (ISSN:00373826)

巻号頁・発行日

vol.56, no.1, pp.7-16, 2008 (Released:2012-05-28)

参考文献数

51

著者

寺澤 美穂 山折 大 勝山 善彦 二村 緑 久富 由里子 田中 章 荻原 朋美 萩原 徹也 杉山 暢宏 鷲塚 伸介 大森 栄

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.43, no.7, pp.362-372, 2017-07-10 (Released:2018-07-10)

参考文献数

23

---

This study analyzed factors affecting plasma lamotrigine (LTG) concentrations in patients with bipolar disorder. The mean concentration/dose (C/D) ratio of LTG was significantly higher in patients co-treated with LTG and valproic acid (VPA) [3.72 (μg/mL)/(mg/kg/day), n = 9] than in those receiving LTG monotherapy [1.76 (μg/mL)/(mg/kg/day), n = 9; P < 0.01]. LTG monotherapy patients were genotyped for UDP-glucuronosyltransferase 2B7 (UGT2B7) *1/*1 (n = 5) and *1/*2(n = 4), whereas VPA co-administration patients were genotyped for UGT2B7*1/*1 (n = 6), *1/*2 (n = 2) and *2/*2 (n = 1). *There were no significant differences in mean C/D ratios between patients carrying the UGT2B7*1/*1 genotype and the 1/*2 or *2/*2 genotype regardless of pharmacotherapy (P ≥ 0.150). In the LTG monotherapy group, the mean C/D ratio was similar in smoking patients [1.52 (μg/mL)/(mg/kg/day), n = 3] and non-smoking patients [1.88 (μg/mL)/(mg/kg/day), n = 6; P = 0.393]. In the VPA co-administration group, however, the mean C/D ratio in smoking patients [2.62 (μg/mL)/(mg/kg/day), n = 4] was significantly lower than that in non-smoking patients [4.61 (μg/mL)/(mg/kg/day), n = 5; P < 0.01]. In vitro studies with HepG2 cells indicated that benzo[a]pyrene, one of the polycyclic aromatic hydrocarbons contained in tobacco smoke, as well as 3-methylcholanthrene efficiently induced expression of UGT1A4 mRNA but not UGT2B7 mRNA and that VPA potently enhanced their induction. These results suggest that concomitant VPA administration and/or smoking may influence LTG concentrations in patients with bipolar disorder.

著者

鈴木 諒太 國實 誉治 荒井 康裕 小泉 明 稲員 とよの 藤川 和久 大森 栄治 関田 匡延 近藤 楽

出版者

公益社団法人 日本水道協会

雑誌

全国会議(水道研究発表会)講演集

巻号頁・発行日

vol.2020, pp.426-427, 2020

著者

中村 裕義 木村 真春 山形 眞一 中村 均 大森 栄 北田 光一

出版者

一般社団法人 日本医療薬学会

雑誌

病院薬学 (ISSN:03899098)

巻号頁・発行日

vol.23, no.5, pp.437-444, 1997-10-10 (Released:2011-08-11)

参考文献数

3

---

In the present study, we examined the effects of light, temperature and humidity on the residual rate of alfacalcidol in four commercially available preparations of alfacalcidol (Alfarol® capsules, Alfarol® powder, Warkmin® capsules and Onealfa® tablets). The tests were performed for up to 10 weeks with PTP seals, or without PTP seals. The changes in residual rate of alfacalcidol in Alfarol® powder packaged with cellophane-laminate paper, and Onealfa® tablets packaged with cellophane-laminate paper after crushing were also examined.The residual rate of alfacalcidol decreased in Alfarol® capsules packaged with PTP seals under fluorescent lighting (1000 lux) and in Alfarol® powder without an aluminum seal under all conditions. There were no changes in the contents of alfacalcidol in Alfarol® capsules with PTP seals and Alfarol® powder packaged by aluminum seal. A slight decrease in the residual rate of alfacalcidol in Warkmin® capsules was found under fluorescent lighting. The residual rate of alfacalcidol decreased in Onealfa® tablets under high temperature and/or high humidity. Alfarol® powder packaged with cellophane-laminate paper and Onealfa® tablets packaged with cellophane-laminete paper after crushing were found to be unstable, indicating that long-term storage should be avoided when these formulations are prepared.